These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
432 related articles for article (PubMed ID: 28801752)
1. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors. Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors. Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362 [TBL] [Abstract][Full Text] [Related]
3. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes. Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949 [TBL] [Abstract][Full Text] [Related]
5. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321 [TBL] [Abstract][Full Text] [Related]
6. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma. Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967 [TBL] [Abstract][Full Text] [Related]
8. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients. Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657 [TBL] [Abstract][Full Text] [Related]
9. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey. Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684 [TBL] [Abstract][Full Text] [Related]
10. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. Engelhardt M; Bertz H; Afting M; Waller CF; Finke J J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272 [TBL] [Abstract][Full Text] [Related]
11. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study. Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study. Sato K; Ishiyama K; Aoki G; Maruyama H; Tsuji N; Tanabe M; Zaimoku Y; Sato H; Yamazaki H; Yamaguchi M; Takami A; Nakao S Int J Hematol; 2019 Dec; 110(6):648-653. PubMed ID: 31542851 [TBL] [Abstract][Full Text] [Related]
14. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF. Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301 [TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors. Tsumanuma R; Omoto E; Kumagai H; Katayama Y; Iwato K; Aoki G; Sato Y; Tsutsumi Y; Tsukada N; Iino M; Atsuta Y; Kodera Y; Okamoto S; Yabe H Int J Hematol; 2022 Jun; 115(6):882-889. PubMed ID: 35397766 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Mueller MM; Bialleck H; Bomke B; Brauninger S; Varga C; Seidl C; Seifried E; Tonn T; Bonig H Vox Sang; 2013 Jan; 104(1):46-54. PubMed ID: 22827736 [TBL] [Abstract][Full Text] [Related]
17. Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors. Pérez-López O; Martín-Sánchez J; Parody-Porras R; Espigado-Tocino I; Noguerol P; Carmona-González M; Pérez-Simón JA Transfusion; 2013 Dec; 53(12):3240-2. PubMed ID: 23489237 [TBL] [Abstract][Full Text] [Related]
18. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Fischer JC; Frick M; Wassmuth R; Platz A; Punzel M; Wernet P Br J Haematol; 2005 Sep; 130(5):740-6. PubMed ID: 16115131 [TBL] [Abstract][Full Text] [Related]
19. Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant. Uddin S; Russell P; Farrell M; Davy B; Taylor J; Agrawal SG Ther Adv Hematol; 2015 Apr; 6(2):53-60. PubMed ID: 25830013 [TBL] [Abstract][Full Text] [Related]
20. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery. Marchesi F; Mengarelli A Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]